Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1

Abstract Background Great progress has been made in applying immunotherapy to the clinical treatment of tumors. However, many patients with triple-negative breast cancer (TNBC) cannot benefit from immunotherapy due to the immune desert type of TNBC, which is unresponsive to immunotherapy. DMKG, a ce...

Full description

Bibliographic Details
Main Authors: Hongpei Tan, Jiahao Liu, Jing Huang, Yanan Li, Qiongxuan Xie, Yuqian Dong, Ze Mi, Xiaoqian Ma, Pengfei Rong
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Journal of Translational Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12967-023-04312-2

Similar Items